Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:IDRANASDAQ:INMBNASDAQ:MBOTNASDAQ:ONVO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsINMBINmune Bio$10.84+2.1%$11.40$6.50▼$14.74$197.29M1.9996,985 shs115,735 shsMBOTMicrobot Medical$0.86-3.4%$1.16$0.86▼$4.37$12.43M1.64122,649 shs68,671 shsONVOOrganovo$0.99-1.0%$1.04$0.89▼$2.05$9.92M0.91820,658 shs72,915 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INMBINmune Bio+2.07%+23.18%-8.75%-10.26%+55.30%MBOTMicrobot Medical-3.12%-3.01%-23.27%-32.03%-43.40%ONVOOrganovo-1.19%-14.08%-5.90%-4.07%-44.18%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AINMBINmune Bio1.2528 of 5 stars3.51.00.00.02.31.70.0MBOTMicrobot Medical2.1223 of 5 stars3.53.00.00.03.70.80.0ONVOOrganovoN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIDRAIdera PharmaceuticalsN/AN/AN/AN/AINMBINmune Bio3.00Buy$16.0047.60% UpsideMBOTMicrobot Medical3.00Buy$7.00710.94% UpsideONVOOrganovoN/AN/AN/AN/ACurrent Analyst RatingsLatest ONVO, IDRA, INMB, and MBOT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIDRAIdera PharmaceuticalsN/AN/AN/A0.29$0.56 per shareN/AINMBINmune Bio$160K1,233.05N/AN/A$2.07 per share5.24MBOTMicrobot MedicalN/AN/AN/AN/A$0.38 per shareN/AONVOOrganovo$370K26.81N/AN/A$1.76 per share0.56Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIDRAIdera Pharmaceuticals$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/AINMBINmune Bio-$30.01M-$1.67N/A∞N/A-19,360.00%-64.11%-45.57%5/1/2024 (Estimated)MBOTMicrobot Medical-$10.74M-$1.08N/A∞N/AN/A-164.13%-125.22%5/15/2024 (Estimated)ONVOOrganovo-$17.26M-$2.17N/AN/AN/AN/A-182.88%-138.52%7/11/2024 (Estimated)Latest ONVO, IDRA, INMB, and MBOT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023INMBINmune BioN/A-$0.47-$0.47-$0.47N/A$0.03 million3/27/2024Q4 2023MBOTMicrobot Medical-$0.25-$0.26-$0.01-$0.26N/AN/A2/8/2024Q3 2024ONVOOrganovo-$0.41-$0.40+$0.01-$0.40$0.08 million$0.01 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIDRAIdera PharmaceuticalsN/A1.561.56INMBINmune BioN/A2.162.16MBOTMicrobot MedicalN/A2.092.09ONVOOrganovoN/A3.673.67OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIDRAIdera Pharmaceuticals12.18%INMBINmune Bio12.72%MBOTMicrobot Medical16.30%ONVOOrganovo8.23%Insider OwnershipCompanyInsider OwnershipIDRAIdera Pharmaceuticals5.05%INMBINmune Bio36.10%MBOTMicrobot Medical10.64%ONVOOrganovo4.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIDRAIdera Pharmaceuticals3262.36 million59.21 millionOptionableINMBINmune Bio1118.20 million11.63 millionOptionableMBOTMicrobot Medical2114.40 million12.87 millionOptionableONVOOrganovo1810.04 million9.64 millionOptionableONVO, IDRA, INMB, and MBOT HeadlinesSourceHeadlineOrganovo gets grant for bioprinted renal tissue for assessing renal toxicity of therapeutic agentspharmaceutical-technology.com - April 24 at 10:28 AMOrganovo (NASDAQ:ONVO) Now Covered by Analysts at StockNews.comamericanbankingnews.com - April 18 at 2:24 AMOrganovo's drug significantly reduces liver fat in NASH studyhealth.economictimes.indiatimes.com - April 16 at 9:35 AMWhy Organovo Stock Is Up Todaymsn.com - April 15 at 2:40 PMOrganovo’s fatty liver disease drug meets main goal in mid-stage studykfgo.com - April 15 at 9:40 AMOrganovo's fatty liver disease drug meets main goal in mid-stage studyreuters.com - April 15 at 8:28 AMOrganovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placeboglobenewswire.com - April 15 at 8:05 AMOrganovo files patent for farnesoid x receptor agonist compound for treating diseasespharmaceutical-technology.com - March 24 at 6:42 PMOrganovo Holdings Stock (NASDAQ:ONVO) Earnings Dates and Earning Callsbenzinga.com - February 24 at 7:35 AMOrganovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - February 10 at 2:25 PMOrganovo Holdings Inc ONVOmorningstar.com - February 9 at 7:39 PMONVO Continues Progressfinance.yahoo.com - February 9 at 2:38 PMOrganovo: Fiscal Q3 Earnings Snapshotsfgate.com - February 8 at 7:40 PMOrganovo Holdings Unveils Corporate Presentation Onlinemsn.com - February 8 at 9:38 AMOrganovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congressfinance.yahoo.com - January 25 at 12:43 PMOrganovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congressfinance.yahoo.com - January 9 at 9:33 AMONVO Shares Experience Surge in Valueknoxdaily.com - January 4 at 10:15 AMChecking in on Organovo Holdings Inc (ONVO) after recent insiders movementknoxdaily.com - January 1 at 6:27 PMOrganovo Holdings: Unregistered Sales Of Equity Securities, Other Events, Financial Statements And Exhibitscbonds.com - December 30 at 8:48 AMOrganovo, Inc.: Organovo Provides Timing for Release of FXR314 Phase 2 NASH Resultsfinanznachrichten.de - December 7 at 8:37 AMOrganovo Provides Timing for Release of FXR314 Phase 2 NASH Resultsfinance.yahoo.com - December 6 at 9:16 AMOVNO Continues Developing Breakthrough Treatmentsmsn.com - November 13 at 4:20 PMCORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Planfinance.yahoo.com - November 13 at 8:43 AMOrganovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)finance.yahoo.com - November 11 at 9:02 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsIdera PharmaceuticalsNASDAQ:IDRAAceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03 develop pre-clinical data in cancer that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Microbot MedicalNASDAQ:MBOTMicrobot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. In addition, it provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.OrganovoNASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.